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Crafting the Perfect Cure? Embryonic CRISPr Editing and Equality of Access
Introduction:
“CRISPr” stands for clustered regularly interspaced palindromic repeats.1 CRISPr based
technologies are transforming the state of life sciences around the world.2 Biotechnology has
advanced through the advent of next generation sequencing technologies, allowing for
researchers to identify individual genotypes quickly and thoroughly and thus identify the genetic
locations of complex diseases.3 By locating the genetic loci of diseases, physicians can provide
more adequate treatment to their patients and recommend lifestyle changes to mitigate disease.4
Genome-editing tools advance biotechnology a step further by permanently mitigating or
eliminating diseases through selective modification of the genome.5
CRISPr has emerged as the premier gene editing tool over its predecessors, zinc-finger
nucleases “ZFNs” and transcription activator-like effector nucleases “TALENs.”6 ZFN and
TALEN are comparatively limited because of the need to engineer a new version of the editing
protein for each genetic target.7 CRISPr only requires a slight alteration to target new sites.8
CRISPr is currently used to generate and engineer changes in thousands of organisms.9 CRISPr
can cure diseases, increase crop yields, and even increase disease resistance in plants and
animals, but much of the spotlight on CRISPr involves controversy.10 The media presence of
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CRISPr has been taken over by talks of the dystopian future of “designer babies,” children
engineered to have augmented traits.11 This controversy was stirred when researcher He Jiankui
announced he edited the germline genome of two twin girls to make them genetically resistant to
HIV.12 Germline edits are controversial because they create heritable changes.13 The results of
the experiment were met by widespread consternation by scientists, ethicists, and the public.14
The experiment was not peer reviewed, went against globally shared research norms and ethics,
failed to comply with government regulations, and overall was performed by staff that lacked
qualifications, training, and experience.15 Suffice to say, He deviated from research norms.16
The resulting public fallout has raised concerns that the future of the field may be in
jeopardy.17 Fred Lanner, a stem-cell scientist at Karolinska University in Stockholm remarked,
“the negative focus is, of course, not good,” others like Jonathan Kimmelman, a bioethicist
specializing in human trials of gene therapies at McGill University in Montreal, Canada, argues
swift action after scandal could drive global cooperation and regulation “that would stimulate,
not hinder, meaningful advance in this area.”18 Due to the He scandal, there has been a conflation
in public sentiment between blatant research infractions and the moral permissibility of heritable
gene editing.19 Studies demonstrate there is no real consensus on the public opinion of the moral
permissibility of heritable gene editing.20 Health care professionals must ensure that public
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understanding of emerging gene editing techniques is driven by careful reflection, racially and
ethnically informed problem solving, high ethical standards, and not scandal.21 Discussions about
CRISPr germline editing should not strictly devolve into talks of ethics surrounding
augmentation and engineering children to embody ideal traits.22 By only focusing on
augmentation and scandal, public discussions on the ethics of the therapeutic applications of
CRISPr will be overshadowed.23 A line should be drawn between CRISPr as a medical
treatment, and as a means of human augmentation. In the near future CRISPr could become one
of the staple therapies in the assisted reproductive technology “ART” framework.24
The rise of IVF and PGT technology has allowed for the reduction of incidences of TaySachs disease in the Ashkenazi Jewish community, rescuing families from the debilitating
childhood disease.25 Other communities that suffer from genetic diseases see reproductive gene
editing as an additional tool for carrier screening and assisted fertility to ensure the conception of
healthy children.26 CRISPr germline editing provides a path to eliminate fatal and debilitating
monogenetic diseases, and its introduction into the ART framework could compliment
preimplantation genetic testing “PGT,” diagnoses.27
This paper argues that CRISPr germline editing is a novel technology that may be utilized
to cure heritable diseases, including diseases that are historically associated with ethnic and
racial minority communities. However, out-of-pocket costs for CRISPr germline therapy will
likely be prohibitively expensive due to the novel nature of the technology and the historic prices
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of other gene therapies. Additionally, because CRISPr germline editing necessitates in vitro
fertilization “IVF,” to cure and then implant embryos, the treatment will likely be classified as an
infertility benefit for insurance purposes. Under the current state law regime there is likely to be
insufficient coverage for CRISPr, thus enhancing inequality to ethnic and racial minorities that
disproportionately suffer from genetic diseases. An expansion of state law mandates to require
private insurance coverage for infertility benefits including IVF, PGT, and CRISPr germline
editing will likely increase coverage for ethnic and racial minorities and thus prevent further
exacerbation of historic inequities in access to treatment.
In Part I this paper will address how CRISPr technology and gene editing operate
generally, how the CRISPr technique works clinically, describe the specific applications of
CRISPr with a focus on CRISPr germline therapies, and discuss the advantages and concerns of
CRISPr germline therapies. In Part II this paper will provide the predicted monetary costs of
CRISPr germline therapy considering both the historic costs of gene therapies and the costs
associated with the ART framework. Part II will also discuss specific insurance provider
coverage of existing infertility benefits. Part III analyzes state insurance laws regarding infertility
coverage and ART therapy. In Part IV, this paper will address historic racial inequities in access
to ART treatments and how an expansion of ART and CRISPr coverage will help address the
prevalence of certain genetic diseases in ethnic and racial minorities. Part V concludes with a call
for careful reflection and inclusive problem solving to ensure ethical standards in gene editing
research are met.
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Part I: Gene Editing, CRISPr Technology, and Applications
A. Gene Editing and CRISPr Generally
“Gene editing” refers to the precise insertion, knockout, and alteration to the genome,
genetic code, of an organism.28 Gene editing tools were once restricted to few select labs, but
thanks to CRISPr gene therapy research has bloomed and now even a high school student can
perform gene editing experiments.29 Older gene editing models produced a genetically altered
mouse in a year or two, but now with CRISPr complex mouse models can be produced within a
couple months.30 CRISPr is not the first site-specific gene therapy used for gene alteration, but
where it revolutionized the field was in its comparative speed and simplicity. 31 CRISPr
technology can modify DNA in organisms and cultured cells quickly, precisely, efficiently, and
for relatively cheap.32 CRISPr is thus prime for use in gene function studies, gene therapy
studies, drug development, and the production of modified crops and livestock. 33 CRISPr can
facilitate the precise editing of genes in both mature and developing organisms.34 Genome
editing with CRISPr seeks to edit genes through “knockout” by inhibiting genes with deleterious
function and “knock-in” by restoring function to mutated genes. 35

Qi Zhou et al., Human embryo gene editing: God’s scalpel or Pandora’s box? , 19 Briefings in Functional
Genomics, 154 (2020).
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B. The CRISPr Technique
CRISPr is naturally found in bacterial genomes and plays a role in bacterial anti-viral
defense, this action is similar to the human immune response. 36 CRISPr repairs the bacterium’s
DNA after a viral attack.37 CRISPr is composed of a guide RNA strand “sgRNA”, which is used
to detect the presence of viral DNA in the bacterium’s genetic code, and a specialized enzyme
known as “Cas,” which carries the RNA around the cell.38 If the guide RNA detects viral DNA,
the Cas enzyme will bind to the viral sequence and cut the DNA at that site.39 The bacterium’s
genetic sequence will then be repaired, and the virus will not be able to reproduce. 40 This process
of destruction and subsequent repair of a bacterium’s genetic sequence proved critical to deriving
the genetic tool CRISPr-Cas9.41 There are many variants of the Cas enzyme, but Cas9 is the
variety of Cas enzyme with the most clinical understanding.42 The CRISPr-Cas9 complex is
often referred to simply as CRISPr.43
CRISPr-Cas9 is known for its versatility, Cas9 can precisely cut double stranded breaks
in DNA that are user directed.44 To edit a cell of interest, Cas9 and sgRNA need to be
introduced, this is normally done through direct injection or a vector.45 The versatility of CRISPr
comes from the customizability of the sequence of the sgRNA strand, which allows researchers
to program Cas9 to make double stranded breaks at specific sites.46 After CRISPr cleaves the
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desired DNA, repair mechanisms are initiated.47 There are two mechanisms of repair, nonhomologous end-joining “NHEJ” and homology-directed repair “HDR.”48 NHEJ is error prone
because reconstruction occurs without a template and is therefore inappropriate if the desired
outcome is to make a dysfunctional gene functional, but is excellent if gene inactivation is
desired.49 HDR rebuilds the DNA via a template strand and is therefore more accurate but is less
efficient than NHEJ repair.50 Improving HDR’s efficiency is a goal of clinical studies to improve
the overall accuracy of CRISPr..51
A key distinction made in CRISPr human genome editing is between somatic cell
therapies and germline cell therapies.52 In somatic editing, alterations to the cells are not passed
on because changes are limited to body cells.53 In germline editing, alterations to the cells are
heritable because changes are made to cells that pass on genetic information. 54 Germline editing
is controversial because of the inherent risks involved with introducing heritable alterations into
the genome.55
CRISPr germline genome editing “GGE,” is used to modify the cells of future organisms
through genetic alterations of sperm, eggs, or fertilized zygotes. 56 CRISPr GGE necessitates the
use of IVF, all published studies utilizing human CRISPr GGE have utilized IVF zygotes. 57
PGT, previously known as preimplantation genetic diagnosis “PGD,” identifies genetically
47
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healthy zygotes in an IVF cohort that will have the highest chances of implantation and can be
used to screen for genetic disease.58 Patients with a familial history of heritable disease may
apply for a PGT-M test to identify and discard embryos in the cohort that carry a disease-causing
allele.59 Implementing CRISPr GGE first requires PGT to test embryos for the disease trait, then
CRISPr would be applied to all embryos, and PGT would be applied again to ensure the genetic
corrections occurred.60
In somatic cell editing, CRISPr edits can occur ex vivo where cells are modified outside
of the patient and reintroduced, or in vivo where CRISPr is directly delivered to the patient’s
body to edit cells.61 There are advantages and challenges with both ex vivo and in vivo methods.62
The advantage for ex vivo procedures are that the procedures are done externally, meaning the
patient is not directly exposed to gene alterations and there is greater control of the process.63
The challenges to ex vivo procedures are maintaining the survival and original function of the
cells outside the patient long enough for gene alteration to occur, and culturing enough cells for
successful reintroduction to the body.64 For in vivo treatments, CRISPr can be delivered
intravenously or through local injection to specific tissues.65 The advantages of in vivo
procedures are that because they are done intravenously or in site-specific areas, there is no need
to create an external cell culture and regraft the cells into the body. 66 However, the challenges of
in vivo procedures are the degradation of the CRISPr components in the body, the potential for
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uneven distribution of CRISPr components at the site of injection, and less control of the overall
procedure.67
C. Specific Applications of CRISPr
CRISPr is a rapidly developing technology and has many potential clinical applications. 68
Cancer immunotherapy and the correction of monogenetic disorders seem to be at the forefront
of clinical research.69 This analysis of the applications of CRISPr will focus on CRISPr GGE
therapy with brief mention of the applications of somatic CRISPr therapies.
a. CRISPr GGE Applications
The scientific community considers CRISPr GGE clinical applications premature, but
future implementation has not been precluded. 70 According to professional recommendations
from the medical community, clinical CRISPr GGE acceptance and implementation requires
adequate safety measures, improved efficacy of methodology, additional societal consensus
approving the technology, and appropriate governance standards to be in place. 71 The most likely
application of CRISPr GGE would be its use to prevent the transmission of heritable diseases.72
In the clinic CRISPr GGE would be paired with IVF to produce a genetically related child that
does not possess a genetic trait associated with a given disease.73 The approach would be
available to couples who present a combination of genotypes that would result in some of their
children being afflicted by a genetic disease, are aware they are potential carriers, and wish to
avoid passing the disease to their children.74 The primary alternative option for the couple would
67
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be to use IVF coupled with PGT to culture, select, and implant a genetically related and
unaffected embryo.75
Theoretically, there are scenarios where PGT would be pointless. 76 If both parents are
homozygous for a recessive gene disorder all embryos would be homozygous recessive as well. 77
Only CRISPr GGE would prevent the transmission of the disorder. 78 Additionally, if one or both
parents are homozygous for an autosomal dominant disorder every embryo will inherit at least
one copy of the dominant disease-causing allele.79 However, both incidences are relatively rare.80
Homozygosity for severe dominant disorders is often lethal at the embryonic level, meaning the
number of sexually mature individuals with homozygous dominant alleles in the general
population is relatively low.81 In the United States, the number of homozygous Huntington’s
disease cases is in the dozens, meaning the probability of needing CRISPr GGE therapy for this
application is minimal.82 For homozygous recessive diseases like sickle-cell disease “SCD” and
Tay-Sachs, the incidence of individuals in the United States that are homozygous recessive are 1
in 3,289 and 1 in 100,000 respectively for the general population.83 However, the incidence of
SCD jumps to 1 in 500 for African Americans and the incidence of Tay-Sachs jumps to 1 in
3600 for those of Ashkenazi Jewish descent because these diseases have a disproportionate
impact on those communities.84 The estimated number of patients that benefit from CRISPr GGE
may be considered relatively rare even in these communities when accounting for the incidence
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of disease, reproductive age, and fertility rates.85 However, that does not justify diminishing the
significance of the technology and how the option may benefit affected families. 86
Another potential application of CRISPr GGE would be to perform a procedure known as
a “rescue embryo.”87 A rescue embryo describes a scenario where PGT testing could screen for
embryos in the cohort with the disease trait, and those embryos would then be isolated and
corrected using CRISPr GGE.88 This method would increase the overall number of viable
embryos in the cohort.89 With current technology CRISPr GGE is most effectively used at the
point of fertilization to avoid mosaicism in the embryonic cells as they divide. 90 Mosaicism
describes when not all cells in the embryo or organism have the same DNA.91 So CRISPr needs
to be applied to all embryos in the cohort to achieve the desired changes.92 However, a method
could potentially be developed to efficiently edits all cells in a multicellular embryo to reduce
mosaicism.93 Prior genetic testing, isolation, and correction of embryos would then become a
possibility.94 Additionally, CRISPr GGE may be the only strategy for an IVF patient with a
genetic condition, that conceived only affected embryos and cannot complete additional cycles
of IVF because of advancing age, disease, or prohibitive cost.95 Genetic enhancement for disease
resistance may also be a possibility but is unlikely to have widespread adoption due to ethical
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concerns. These ethical concerns are pervasive for the genetic enhancement of complex traits
like intelligence.96
In one experiment, CRISPr GGE was used to save human induced pluripotent stem cells
and mice from the deleterious gene that causes spinal muscular atrophy “SMA.”97 The
experiment was a proof of concept to determine if CRISPr could therapeutically intervene in
SMA and other RNA-splicing diseases.98 SMA is a degenerative motor illness that in severe
cases leads to muscle weakness, muscle degradation, and eventually death.99 SMA is the most
common inherited cause of infant mortality in the world, and 98 percent of SMA patients are
homozygous for the deletion of an SMN1 gene.100 Results showed CRISPr, “rescued the SMA
phenotypes in human induced pluripotent stem cells and in germline-corrected SMA mice.”101
The lifespan of the SMA mice improved from about 400 days to approximately 600 days. 102 The
mice saved by CRISPr GGE disruption demonstrated increased lifespans, increased body weight
and motor function, and increased motor neurons.103 The results were inconclusive as to the
feasibility of CRISPr having the same effect in humans, but still provide a proof -of-concept for
CRISPr’s ability to rescue SMA mice from a debilitating disease. 104
Various animal models have utilized CRISPr GGE including primates.105 Studies have
also utilized GGE to correct mutations with heart disease and beta-thalassemia.106 However,
96
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additional testing needs to be performed before CRISPr GGE gene editing can become part of
everyday patient care.107 Somatic therapies are not always the optimal choice. 108 For example, in
cases where early-onset or congenital diseases occur, the symptoms of the disease would already
affect the child before somatic therapy could ameliorate the condition. 109 In lysosomal storage
disorders the disease manifests virtually no symptoms in infants but within the first days of life
the disease proves fatal.110 Additionally, in the case of Duchenne muscular dystrophy “DMD”
symptoms manifest within the first five years of life, but after the symptoms have appeared the
condition is virtually irreversible.111 Huntington’s disease also presents an issue for somatic
therapy in that the targeted tissue designated for therapy is hard to access in a fully formed
child.112 CRISPr GGE comparatively can easily target a gene within a gamete or zygote in vitro
when a parent is a known carrier of the genetic disorder. 113 There is no need to worry about
targeting multiple widespread and different types of tissue to accomplish therapy. 114
Potential targets of CRISPr GGE in cardiovascular medicine include hypertrophic
cardiomyopathy “HCM,” DMD, and other heritable arrhythmic disorders; all three diseases are
heritable and lack effective therapy making them prime for CRISPr GGE therapy.115 HCM is a
cardiac disease that leads to degenerative heart failure.116 DMD is a disease that leads to
progressive muscular weakness and ultimately heart failure.117 Heritable arrhythmic disorders
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cause sudden cardiac death in young children.118 All these disorders are caused by a single gene
mutation.119 In one United States study, viable human embryos were modified to correct for the
genetic traits that cause HCM.120 HCM is responsible for the most cardiac deaths under the age
of thirty.121 The study proved promising, but additional studies are needed to improve the
efficiency of the CRISPr complex before clinical applications may be considered.122
b. CRISPr Somatic Therapy Applications
While this paper does not focus on the applications of somatic gene therapies it is
noteworthy that these therapies have seen success in clinical cancer immunotherapy and gene
disruption therapy.123 In 2018, the FDA approved a CRISPr clinical trial for cancer
immunotherapy, the goal of the clinic was to modify T-cells to target several forms of cancer
with relapsed tumors.124 Another successful clinical trial using CRISPr treatment aimed to
provide therapeutic benefits to patients with SCD and later beta-thalassemia by utilizing gene
disruption to increase fetal hemoglobin levels. 125 The previous trials both used ex vivo
modification of cells, which is the most common form of somatic CRISPr therapy. 126
Approaches using in vivo techniques have been limited in their clinical applicability because of
inadequate access to target tissues. However, some organs, like the eye, are accessible. 127 In one
promising treatment, CRISPr components can be delivered directly into the retina to treat
patients with Leber congenital amaurosis “LCA,” a monogenetic disease that causes childhood
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blindness.128 Somatic CRISPr therapies are better suited to treat complex disorders like artery
disease and atherosclerosis because of the complicated interplay between genetics and
environmental factors that cause these diseases.129
D. Limitations and Advantages of CRISPr GGE
a. CRISPr GGE Limitations
CRISPr GGE experiments create hefty public discourse surrounding issues of safety and
ethical supervision.130 Safety issues involve a contradiction between promising technological
outcomes and faults caused by the technology’s immaturity. 131 Safety concerns of CRISPr GGE
include off-target effects, chimeric embryos, and the bad-gene good-gene contradiction.132 Offtarget effects occur when the CRISPr complex mismatches with a non-target DNA sequence and
an unintended mutation is introduced.133 This posits the problem that the unintended mutation is
now heritable and passed on to the next generation despite its effects being unknown. 134 .
Research is underway to improve the specificity of CRISPr and the method of detection for offtarget effects to increase the feasibility of CRISPr GGE therapies.135 Another concern are
chimeric embryos, otherwise known as mosaicism. 136 Mosaicism in GGE is caused by the Cas9
protein not fully degrading before the zygote replicates, which results in a mosaic of cells that
have different DNA.137 The hazard of mosaicism depends on degree of change and the
chromosome where the alteration occurred. 138 Using an enzyme that is more precise and
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controlled in its timing of enzymatic activity may limit the effects of mosaicism. 139 The bad gene
good gene contradiction is best described as researchers not fully comprehending all the positive
and negative effects of genes, which necessitates a humility when modifying genes to delete a
perceived bad gene.140 For example, the mutation of hemoglobin that causes SCD also prevents a
patient from catching malaria.141 Human CRISPr GGE cannot be approached from the
perspective of simply deleting bad traits, rather additional research needs to be done on the
cause-and-effect relationships between genes before permanent genomic changes occur.142
b. CRISPr GGE Advantages
The clinical value of CRISPr GGE has many applications, CRISPr GGE aims to increase
the knowledge and understanding of human development as well as gene functionality,
ameliorate genetic defects during development, and treat diseases. 143 CRISPr GGE could
potentially cure the 6000 known human genetic diseases that afflict twelve percent of the world’s
population.144 CRISPr GGE has an advantage over somatic therapies for treating monogenetic
diseases with a wide range of heritability like muscular dystrophy, and genetic diseases that are
difficult to treat in fully grown individuals like Huntington’s disease.145 Population control of
disease is a broader justification for CRISPr GGE, such that through its use the prevalence of
genetic diseases will be diminished.146 This prognosis requires the delicate balancing of the
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benefits to society, like the economic gains of diminished costs to the healthcare system, against
the potential harm to individuals through the introduction of unknown heritable mutations. 147
Part II: Monetary Costs of IVF, PGT, and CRISPr GGE
According to Stanford bioethicist Mildred Cho, PhD, “Gene therapy is not the same as
taking a pill from the pharmacy, it’s more like getting an organ transplant…Cancer
immunotherapy already costs in the hundreds of thousands of dollars per year. There’s no way
that gene-edited treatments are going to be any less expensive.” 148 New biotechnologies used to
treat diseases often present a high price tag because gene therapies are difficult to research, are
inordinately costly to push through clinical trials, are uncertain in success rate, serve a limited
population, and are by their nature permanent.149 Gene therapies are not like insulin, the aim of
gene therapy is to pay for the treatment once and be cured .150 For example, the Novartis drug
Zolgensa is an FDA approved one-time gene therapy treatment of SMA.151 The drug is priced at
$2.125 million and insurers may pay this amount in yearly installments of $425,000 per year. 152
The price of Zolgensa was calculated by Novartis as half the approximate $4 million cost of
managing the disease over the course of a decade.153 Another expensive gene therapy is the
Sarepta Therapeutics drug Eteplirsen.154 Eteplirsen is a novel drug aimed to treat DMD, however
the drug was largely denied coverage by insurance companies due to the drug’s poor efficacy in

147

Id.
Mark Shwartz, Target, delete, repair CRISPR is a gene-editing tool that's revolutionary, though not without risk,
Stanford Medicine, https://stanmed.stanford.edu/2018winter/CRISPR-for-gene-editing-is-revolutionary-but-itcomes-with-risks.html (last visited December 12, 2020).
149 Jacob S. Sherkow, CRISPR, Patents, and the Public Health, 90 Yale J. Biology & MED. 667 (2017).
150 Id.
151 Ken Alltucker, A new drug costs $2.1 million for children with a muscle-wasting disease, USA Today,
https://www.usatoday.com/story/news/health/2019/05/24/zolgensma-2-1-million-drug-nations-most-expensive/
(May 24, 2019).
152 Id.
153 Id.
154 Sherkow, supra note 149 at 669.
148

17

clinical trials and its $750,000 annual price tag.155 There is hope for CRISPr GGE coverage,
insurance providers rarely refuse to cover novel therapies and work through prescription benefit
managers to reduce pharmaceutical drug prices if the therapy is proven effective.156
An important consideration for CRISPr price is patent protection.157 As CRISPr has
progressed toward clinical testing, the dispute over patent ownership has expedited, primarily
because the market valuation of the CRISPR technology is in the billions. 158 The dispute for
CRISPr ownership is between the University of California, along with the University of Vienna
and Umea University, collectively “UC”, and the Broad Institute who is partnered with MIT and
Harvard, collectively “Broad Institute.”159 Both UC and the Broad Institute have filed for patent
ownership to ascertain a monopoly over the CRISPr market in the United States and in
Europe.160 The costs of this heated litigation are likely to be passed on to consumers when the
litigation resolves and CRISPr enters clinical trials.161
If CRISPr GGE therapy were to underperform in clinical trials and was exorbitantly
priced due to patent pressures, it is likely insurance companies would deny coverage.
To approximate the cost of CRISPr GGE therapy it is important to draw comparisons to
IVF and PGT because CRISPr GGE treatment requires use of both technologies.162 ART
therapies are most pervasive in affluent countries.163 IVF and PGT present the necessary
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framework for couples affected by genetic disorders to conceive a healthy child.164 The
demographic most likely to utilize ART therapies are wealthier patients, which is defined by a
household income of greater than $100,000 per year.165 Under the current insurance regime,
patients often must pay first and seek reimbursement later.166 Insurers frequently do not agree to
coverage in advance of treatment and instead make a coverage decision on a case-by-case
basis.167 Given the unpredictability of length and cost of ART treatment, stress and uncertainty
are necessarily increased in patients facing the hurdle of relying on coverage for treatment.168
This stress is exacerbated by couples having to budget both ART treatment and adding a new
child to their household.169 Cost raises the ethical concern of how much couples will value
having a child; couples are faced with an ethical dilemma of choosing between solvency and
procreation.170 On average, an IVF cycle can cost from $9,226 to $12,513 per cycle, with PGT
adding an additional $2,500 to $6000 per cycle.171 According to the CDC, successful pregnancy
and live birth often requires more than one cycle of ART.172 Factors that increase the required
number of cycles include age, weight, height, previous IVF usage, and prior pregnancies.173
Cost remains the most salient factor and barrier to couples deciding to undergo ART
treatment.174 Couples are motivated to geographically shop for states that mandate coverage for
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IVF if their insurance provider does not provide coverage.175 Affordable reproductive
technologies allow more couples the ability to avoid genetically prone diseases and ensure a
higher quality of life for their children.176 Most U.S. insurers including United Healthcare, Aetna,
Cigna, and Anthem cover genetic testing.177 To qualify, individuals usually need to attend
genetic counseling or present a genetic risk based on family history.178 United Healthcare
explicitly carves out screening options for Ashkenazi Jewish carrier screening, whereas other
insurers typically enumerate genetic diseases without mention of ethnicity or race. 179 Genetic
testing is also available to consumers for a few hundred dollars; this option may be helpful for
individuals who lack insurance or want definitive privacy in their genetic results from their
insurer.180 Additionally, some health insurance companies provide coverage for IVF and PGT
independent of state mandates.181 Aetna provides coverage for IVF when the policyholder has
ART benefits and the procedure is medically necessary.182 For Aetna, medically necessary is
defined as medical diagnosis of infertility, which in turn means less invasive fertility methods
did not result in pregnancy.183 Aetna will cover PGT if there is a need to diagnose specific,
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detectable single gene mutations.184 Cigna also offers coverage for the combination of IVF and
PGT if there is a medical diagnosis of infertility, of which the definition is similar to Aetna.185
United Healthcare includes coverage of IVF for reasons of infertility, but causes outside of
infertility must be reviewed in accordance with the benefit plan.186 PGT is offered by United
Healthcare for the diagnosis of known genetic disorders, unless there are specific exclusions in a
particular plan.187 It is important to recognize that the costs of CRISPr GGE and IVF are
significantly less than the lifelong medical costs accrued because of the genetic disorder.188 For
this reason, insurance providers may be incentivized to cover treatments like CRISPr that reduce
healthcare costs over the life of the individual.189
Currently, two options exist for prospective parents with a known genetic risk to ensure
their biological children do not inherit the genetic condition. 190 These options are prenatal
diagnosis “PND,” and PGT.191 PND involves natural conception and a subsequent test for
genetic abnormalities.192 If the condition is found, the pregnancy may be terminated.193 PGT
screens for embryos free of the genetic disease.194 PND is covered by almost every public and
private insurer in the United States.195 PGT functions in the same diagnostic capacity as PND,
just in earlier stages of pregnancy.196 Therefore, cost is likely the primary reason insurers deny
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PGT coverage since PND is a cheaper alternative.197 The United States Centers for Medicare &
Medicaid Services “CMS” present guidelines for what qualifies as medically necessary care. 198
Medically necessary care consists of “health care services or supplies needed to diagnose or treat
an illness, injury, condition, disease or its symptoms and that meet accepted standards of
medicine.”199 PGT certainly qualifies as a diagnostic procedure, but it may be overshadowed in
the insurance framework by the cheaper diagnostic procedure PND.200 The argument for PGT as
a treatment procedure seems attenuated.201 However, if CRISPr GGE were to meet the accepted
standards of medicine threshold through clinical research, it could fulfill the treatment
component of the medically necessary definition for ART therapy since CRISPr GGE directly
alters the genome to treat disease.202 Perhaps if the ART framework met both definitions of
medically necessary, insurers would be more prone to extend coverage.203
Part III: State Law ART Regulations
A comparative analysis of state private insurance coverage laws regulating infertility
treatments demonstrates a great disparity between even the states that mandate some form of
infertility coverage.204 Some states may cover fertility testing alone, whereas others cover
multiple cycles of IVF.205 The federal government does not mandate infertility coverage as an
essential benefit through the Affordable Care Act “ACA”, leaving states to decide whether to

197

Id.
Id.
199 Id.
200 Id.
201 Zhou et al., supra 28 at 157.
202 Id.
203 Kilbride, supra note 180 at 4.
204 Louise Norris, Does the ACA require infertility treatment to be covered by health insurance? , Health Insurance &
Health Reform Authority, https://www.healthinsurance.org/faqs/does-the-aca-require-infertility-treatment-to-becovered-by-health-insurance/ (Oct. 26, 2020).
205 Id.
198

22

mandate insurance companies to provide coverage.206 Currently, nineteen states mandate some
form of coverage for infertility treatment, whereas thirty-one states and DC have remained silent
on the issue.207 There does seem to be a trend towards mandating coverage; since 2018,
Colorado, Delaware, New Hampshire, and Utah have all passed legislation addressing infertility
coverage.208 Colorado’s mandate will take effect in January of 2022, New Hampshire’s mandate
took effect in January of 2020, and Maryland will expand its coverage as of 2021.209 Fifteen
states have laws requiring health plans to cover at least some infertility treatments.210 Colorado
will join these states in 2022.211 Two states, Texas and California, require group health plans to
offer at least one policy with infertility coverage, but employers can opt for a different plan. 212
One state, Louisiana, prohibits coverage from being excluded based on the diagnosis of a
correctable medical condition that results in infertility.213 This law does not mandate IVF or
other fertility drug treatments.214 Nine states that lack a mandate to cover, as well as DC, have a
benchmark plan to provide most individual and small group plans sold in the state with
diagnostic and possibly treatment services.215 Thirteen states have laws that mandate IVF
coverage including, Arkansas, Colorado in 2022, Connecticut, Delaware, Hawaii, Illinois,
Maryland, Massachusetts, New Hampshire, New Jersey, New York, and Rhode Island.216
Including Colorado, sixteen states have laws mandating at least genetic testing or other
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diagnostic tests.217 The CDC has deemed Illinois, Massachusetts, New Jersey, and Rhode Island
comprehensive coverage states.218 A comprehensive coverage state is defined as offering at least
four egg retrievals within the state mandate.219 No state mandates PGT.220 Many mandate to
cover states have exemptions for small employers that employ less than fifty people as well as
religious exemptions.221 State laws also do not apply to self-insured plans.222 A self-insured plan
describes when an employer pays for the health services of its workers rather than by purchasing
health insurance.223
In California, group insurers must offer coverage for infertility treatments and diagnosis,
but they are not required to provide the coverage, nor do employers need to include it in their
insurance plans.224 The state mandate notably excepts IVF from coverage.225 Infertility is defined
by the law as a demonstrated condition, recognized by a licensed physician and surgeon as a
cause of infertility; or the inability to conceive pregnancy or fully carry a live birth to term after a
year or more of sexual relations absent contraception.226 The law further carves out an exception
for religious employers stating they do not offer coverage that is inconsistent with the
organization’s religious or ethical principles.227 There was a notable amendment that specified
treatment, “shall be offered and, if purchased, provided without discrimination on the basis of
age, ancestry, color, disability, domestic partner status, gender, gender expression, gender
identity, genetic information, marital status, national origin, race, religion, sex, or sexual
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orientation.”228 As evidenced by the law, California’s state mandate of infertility coverage is
extremely conservative in its application.
New Jersey law requires health insurers with 50 or more employees that provide
pregnancy related coverage of medically necessary expenses incurred in diagnosis and treatment
of infertility, including IVF, artificial insemination, diagnosis and testing, embryo transfer,
surgery, medications, gamete intrafallopian transfer, zygote intrafallopian transfer,
intracytoplasmic sperm injection, and four completed egg retrievals per lifetime of the covered
person.229 IVF is further expanded, coverage includes both using donor eggs and when an
embryo is transferred to a surrogate.230 Notably infertility treatments that are experimental or
investigational are not covered as well as cryopreservation of gametes.231 Coverage of IVF,
zygote intrafallopian transfer, and gamete intrafallopian transfer are only required if the patient
has used all reasonable less expensive options covered by insurance and still has not become
pregnant, the maximum number of egg retrievals has not been used, the person is under 46 years
old, and the procedures are performed at facilities conforming to the American Society for
Reproductive Medicine “ASRM” or the American College of Obstetricians and Gynecologists
“ACOG.”232 New Jersey defines infertility broadly in accordance with the ASRM and ACOG to
include a disease or condition that results in abnormal function of the reproductive system
including where a couple cannot get pregnant after two years of unprotected sex, where the
female partner is under the age of 35; or one year of unprotected sex where the female partner is
over the age of 35; or when a couple is unable to carry a pregnancy to term.233 New Jersey also
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has a similar religious organization exemption to California where coverage can be excluded if it
is contrary to a religious employer’s bona fide religious tenets.234 New Jersey’s laws are
comprehensive in their mandate to cover, especially when compared to California.
Illinois law also requires insurers to provide coverage for infertility treatment, but is even
more liberal in that employers with fewer than 25 employees do not need to provide coverage. 235
Infertility is defined in Illinois as the inability to conceive after one year of unprotected sexual
intercourse or the inability to sustain a pregnancy.236 Otherwise, Illinois coverage provides for
the diagnosis and treatment of infertility, IVF, uterine embryo lavage, embryo transfer, artificial
insemination, gamete intrafallopian transfer, zygote intrafallopian transfer and low tubal ovum
transfer.237 To utilize IVF, zygote intrafallopian transfer, and gamete intrafallopian transfer the
patient must not have been able to sustain a successful pregnancy through less costly infertility
treatment covered by insurance.238 A religious exemption is also carved out.239 Additionally, the
patient is covered by four egg retrievals unless a live birth occurs, then only two more retrievals
are covered.240 Compared to New Jersey and California, Illinois law places the least amount of
restrictions on ART treatment. Although both New Jersey and Illinois are comprehensive in their
mandates, fundamental differences can still be observed in how that coverage is attained, most
notably the lack of an age barrier to attain treatment in Illinois law.
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Part IV: CRISPr GGE and Benefits to Ethnic and Racial Minorities
A. Inequity of Access to ART therapy
Under the current insurance regime there is concern that if CRISPr GGE were clinically
available it would be prohibitively expensive, not covered by private insurance, and thus limited
to socio-economic classes that can afford out-of-pocket treatment. Lack of access to treatment
would exacerbate already existing health inequities in ethnic and racial minorities. An expansion
of state law mandates to require private insurance coverage for infertility benefits including IVF,
PGT, and CRISPr GGE will likely increase coverage for ethnic and racial minorities and thus
address disparate ethnic and racial outcomes in health.
In the United States race and ethnicity are often linked to a disproportionate access to
healthcare affecting primarily Hispanic and Black patients.241 In states that mandate insurance
coverage of IVF, the utilization of ART therapy by Hispanic and Black Non-Hispanic women,
aged fifteen to forty-four, nearly doubled when compared to states without an insurance mandate
for IVF treatment.242 The main factor contributing to ART use is affordability, when ART
therapy is not covered by insurance it can impose great financial hardship on couples.243 Socioeconomic factors can indicate ART use; women with higher income and higher levels of
educational attainment are more likely to utilize ART.244 Residential segregation of certain
minority groups into areas with lesser economic opportunities can present an economic barrier to
access fertility options.245 Even when coverage is mandated, rates of ART use among Hispanic
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and Black women are still less than White and Asian/Pacific Islander women. 246 However, this
disparity is thought to be caused by out-of-pocket expenses like deductibles and copays, as well
as non-economic factors such as the negative communal stigma on infertility.247 To reduce this
disparity, health care providers could provide incentives for infertility clinics to operate in lower
income areas.248 Increasing awareness, affordability, and expanding access to low-income areas
may be enough to defeat communal stigmas and increase equitable access to ART therapy. 249
Minority communities are aware of disparities in the distribution of cutting-edge medical
technology, and that potential genetic enhancements from CRISPr may exacerbate health
disparities in these communities.250 American socioeconomic status has a strong association with
race and ethnicity, which raises concerns that if CRISPr treatments were limited to out -of-pocket
payments, racial and ethnic minorities would not equally share in the fruits of gene therapy. 251
Gene therapy may pose a risk of widening health disparities, but if scientists, physicians, and
healthcare policymakers pledge to ensure justice in gene therapy, the technology may be used as
a tool to eventually reduce health inequities.252
B. Prevalence of Certain Genetic Conditions
Fairness and equitable access must be at the forefront in developing GGE CRISPr policy.
Underserved patients must share in equal access to ground-breaking biotechnologies through a
collaborative dialogue and policy decisions informed by the needs of underserved populations.
The National Academics of Science Engineering and Medicine has delineated seven principals

246

Id.
Id.
248 Id.
249 Id.
250 Hildebrant & Jonathen, supra note 52 at 827.
251 Id. at 828.
252 Id.
247

28

for the governance of human genome editing: the science should promote wellbeing, increase
transparency to the community, take due care in research studies, follow the standards of
responsible science, respect persons right to autonomy and integrity, be fair in the distribution of
risks and burdens, and support transnational cooperation and collaboration.253
Clinical applications of CRISPr GGE for ethnic and racial minorities will be to correct
mutations in zygotes that cause fatal or debilitating monogenetic diseases.254 Certain
monogenetic diseases have a higher incidence rate in ethnic and racial minority communities.255
Such diseases include SCD, Ty-Sachs, and beta-thalassemia.256 The corrected gene would then
be heritable and passed on to the next generation.257 The prevalence of genetic diseases in these
communities would thus be reduced.258 Reducing incidence of disease would diminish economic
strains and increase the number of healthy children born.259 Economic strains include the cost of
lifetime management of disease for the individual and their family.260 Economic strains on the
healthcare system would also be reduced. 261
The most common monogenetic disorder caused by a single point mutation is SCD,
making the disease a prime target for CRISPr GGE therapy. 262 SCD also has a disproportionate
impact on those of African descent.263 Currently, more than 100,000 people in United States live
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with SCD, the incidence of which is disproportionately Black.264 SCD occurs in one in every 365
Black births, with sickle cell trait “SCT” occurring one in every thirteen Black births.265 Sickle
cell trait describes a condition where the child has one abnormal allele but does not show the
severity of SCD symptoms.266 The first signs of SCD appear during the first year of life, usually
around five months.267 The symptoms can range from mild to severe, and the disease worsens
over time.268 The characteristic symptoms include acute pain crises, swelling in the hands and
feet known as hand-foot syndrome, acute chest pain similar in feeling to pneumonia, as well as
anemia and the associated symptoms of dizziness, tiredness, irritability, and difficulty
breathing.269 SCD requires a lifetime of management of lifestyle and potentially necessitates a
lifetime of medications.270 The SCD community has been historically disenfranchised and there
has been little advancement on the ease of access of SCD treatments.271
Tay-Sachs disease is a fatal genetic disorder that causes the progressive degeneration of
the central nervous system.272 Children born with Tay-Sachs appear unaffected at birth and
symptoms do not appear until about four or six months of age. 273 The child will begin to lose
motor skills and gradually lose the ability to see, hear, and swallow. 274 By two years old, most
children diminish in mental function.275 The child eventually becomes completely cognitively
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impaired, paralyzed, and unable to respond. 276 Death usually occurs by age four.277 Tay-Sachs
disease has no cure.278 The incidence of Tay-Sachs is much higher in individuals of Ashkenazi
Jewish descent, with an estimated one in twenty-five individuals being a carrier for the
disease.279 Since Tay-Sachs does not have an effective cure, possesses no genetic benefits to the
individual, and has a disparate impact on an ethnic minority, CRISPr GGE therapy will be an
optimal treatment to reduce the incidence of Tay-Sachs in the Ashkenazi Jewish community. 280
Beta-thalassemia is a blood condition that impacts the production of hemoglobin.281 The
disease has two forms, thalassemia intermedia and thalassemia major. 282 Thalassemia intermedia
appears in early childhood and is characterized by symptoms of weakness and anemia. 283
Thalassemia major can become life-threatening, children with major develop progressively
worse anemia and have reduced immunity.284 Thalassemia major may require regular blood
transfusions.285 Beta-thalassemia has a high incidence amongst the Hispanic community, with
between one in thirty and one in fifty individuals being a carrier for the disease. 286
Part V: Conclusion
All people should share in the breakthroughs of scientific discovery, classes of people
should not be denied access to technology that can ensure a healthier life for their progeny based
solely on personal wealth and the availability of coverage. If CRISPr is left to only those who
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can afford out-of-pocket costs, future generations of already marginalized communities will be
further disenfranchised through the denial of access to therapy that seeks to diminish genetically
prone diseases. In equity and in fairness, state infertility mandates should be expanded to afford
ethnic and racial minorities a greater opportunity to share in the fruits of emerging
biotechnologies. Minimum standards that need to be established before CRISPr GGE can be
adopted include, the development of acceptable methodologies for measuring off-target effects,
establishing an acceptable threshold of allowable off-target mutations, and setting precedent for
when CRISPr GGE may be utilized.287 Ethical considerations must be undertaken in human GGE
research to set a boundary between therapeutic treatment and genetic enhancement of
individuals. Human GGE research must ensure the principles of beneficence and justice are
respected through research and innovation. Healthcare professionals can ensure justice and
ethical regulation by defining the relevant stakeholders of GGE research, establishing ethics
committees to review and supervise research, and by maintaining public contact to stay informed
on the needs of society.
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